Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that dosing has been completed in its animal study evaluating formulation enhancements with two next-generation glucagon-like peptide-1 drugs, retatrutide and amycretin, according to a company press release.

The study examines the compatibility of these drugs with Lexaria's DehydraTECH drug delivery technology. Retatrutide, owned by Eli Lilly and Company, is a triple hormone receptor agonist currently administered via weekly injections. The compound targets GLP-1, glucagon, and glucose-dependent insulinotropic polypeptide receptors.

Lexaria's study investigates oral dosing formulated via tablets and capsules for both retatrutide and amycretin, which is owned by Novo Nordisk. The research includes 18 different study arms to evaluate new DehydraTECH compositions, with blood samples taken at multiple timepoints through a 24-hour post-dosing period.

"We have already established the compatibility of our technology with today's leading GLP-1 drugs, but if we are likewise able to demonstrate benefits with the drugs of tomorrow like retatrutide, amycretin and others, then we will begin to show relevance to those drugs that will likely be on the market for the next 10 years or more," said Richard Christopher, CEO of Lexaria Bioscience.

The study aims to investigate pharmacokinetic performance and tolerability while comparing pill formulations to capsules. The research examines absorption differences between the stomach and intestine delivery methods.

The study evaluates alternative formulations to salcaprozate sodium technology used in Novo Nordisk's oral products, including compositions using sodium caprate as a delivery enabling compound. Lexaria funded the study from existing corporate resources.